Table 1.
Characteristics of included studies.
| Outcomes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Migraine intensity | MIDAS | ||||||||||||
| Study | Country | Study design | Population | Age (mean) | Male % | Sample size | Type of surgery/intervention | Baseline mean (SD) | Final mean (SD) | Baseline mean (SD) | Final mean (SD) | 50% MHI reduction (%) | Follow-up duration |
| Albano et al., 202328 | USA | Prospective observational study | Chronic migraine patients failed drug therapy | 43 | 18 | 34 | Decompression or neurectomy | NA | NA | 57 (87) Median | 20 (59) Median | NA | 20.7 mo |
| Behin et al., 200532 | USA | Prospective observational study | Migraine patients failed at least three drugs | 45 | NA | 21 | Functional Endoscopic Sinus Surgery | 7.8 (1.5) | 3.6 (3.7) | NA | NA | NA | 62 mo |
| Dirnberger et al., 200427 | USA | Prospective observational study | Migraine patients not responding to drug therapy | NA | NA | 60 | Nerve Decompression | NA | NA | NA | NA | 40 | Six months |
| Gfrerer et al., 201926 | USA | Prospective observational study | Refractory migraine Patients | 45 | 14 | 85 | Nerve Decompression | NA | NA | NA | NA | 82 | 12 mo |
| Ghazisaidi et al., 201234 | Iran | Prospective observational study | Patients with a refractory migraine and deviated nose | NA | NA | 24 | Septorhinoplasty | 8.9 (8–10) | 0.72 (0–3) | NA | NA | NA | 31 mo |
| Hann et al., 201329 | USA | Prospective observational study | Polypharmacological therapy failed chronic migraine patients | 41.5 | 21 | 14 | Occipital nerve stimulation | 7.32 (2.4)a | 3.4 (2.3) | NA | NA | NA | 31 mo |
| Mekhail et al., 201638 | USA | Randomized, Double-blind, Controlled trial | Chronic migraine patients failed drug therapy | 44.6 | 25 | 13 | Occipital nerve stimulation | 7.29 (1.20) | 5.14 (2.25) | 168 (55.36) | 86.43 (73.58) | NA | 13 mo |
| Miller et al., 201739 | UK | Prospective cohort study | Intractable chronic migraine | 47.7 | 24 | 53 | Occipital nerve stimulation | 6 (1.71) | 4.66 (2.59) | 154.91 (84.03) | 134.28 (92.7) | NA | 42 mo |
| Omranifard et al., 200440 | Iran | Prospective, randomized, controlled trial | Migraine patients not controlled by drug treatment | 42.2 | 12 | 25 | Nerve Decompression | 8.31 (0.28) | 4.06 (0.18) | NA | NA | NA | 12 mo |
| Rodrigo et al., 201735 | Spain | Prospective observational study | Chronic migraine patients with poor response to drug | 46.9 | NA | 35 | Occipital nerve stimulation | 9.1 (0.64) | Decreased by 4.9 (2.0) | NA | NA | NA | 112.8 mo |
| Schwedt et al., 20079 | USA | Retrospective observational study | Medically intractable migraine | 39 | 20 | 15 | Occipital nerve stimulation | 7.1 (1.3) | 4.7 (2.2) | 178 (80) | 109 (92) | NA | 19 mo |
| Serra et al., 201237 | Italy | Randomized cross-over study | Chronic refractory migraine | 46 | 34 | 29 | Occipital nerve stimulation | NA | NA | 79 (30–135) | 10 (0–20) | NA | 12 mo |
| Silberstein et al., 201231 | USA | Prospective, randomized, controlled trial | Refractory chronic migraine Patients | 45 | 22.9 | 105 | Occipital nerve stimulation | 5.99 (1.68) | NA | 158.4 (76.8) | Reduced by 64.6 points | NA | 18.3 mo |
a
Calculated by adding mean follow-up score and mean reduction score.
NA, Not available.